Stanley Black & Decker Investing $1 Billion in the U.S. to Drive Innovation, Strengthen U.S. Manufacturing Footprint and Expand the Skilled Trades Workforce Essential to Building America’s Infrastructure

NEW BRITAIN, Conn., Aug. 12, 2026 /PRNewswire/ — As U.S. infrastructure investment accelerates, the construction sector faces a critical challenge: deploying cutting-edge tools and technologies to boost productivity while closing a widening skilled trades gap, with nearly half a million new workers needed by 2027. Against this backdrop, Stanley Black & Decker (NYSE: SWK) is investing $1 billion in the U.S. to advance innovation, develop next-generation tools and solutions, and increase access to training opportunities to expand the skilled trades workforce.

“Our U.S. investment strategy has multiple dimensions and goes far beyond expanding manufacturing – it’s about igniting innovation, building world-class capabilities, and redefining the future of work in America,” said Chris Nelson, Stanley Black & Decker’s President and Chief Executive Officer. “By leaning into research and development and investing in the future of our U.S. operations, we are setting the benchmark for next-generation products and solutions. These investments will empower America’s tradespeople to work safer, reach new levels of productivity, and rise to help solve the nation’s toughest challenges. This is how we plan to lead America forward – by building, competing, and innovating.”

Of the $1 billion Stanley Black & Decker plans to invest through 2028, approximately 50% will go to research and development to accelerate the creation of next-generation tools and breakthrough solutions for trades professionals. The other 50% will support capital expenditures and long-term investments to further strengthen its U.S. manufacturing footprint and support new product development. In addition, Stanley Black & Decker has committed to investing $60 million through its DEWALT Grow the Trades initiative through 2030 – of which $27 million has already been deployed – to expand training programs and open new pathways to rewarding careers in the skilled trades.

“By advancing technology, investing in U.S. manufacturing and expanding training to skilled trades Stanley Black & Decker is helping to build a stronger workforce and a more resilient future for communities across the nation,” said Nelson.

Jay Timmons, President and CEO of the National Association of Manufacturers, underscored the far-reaching impact of Stanley Black & Decker’s investment in the United States. “For more than 180 years, Stanley Black & Decker has helped define what it means to make things in America – innovating, investing and creating opportunities for manufacturing workers and the communities they serve. Their commitment to strengthening U.S. manufacturing and empowering America’s manufacturers exemplifies the leadership our nation needs. These investments not only reinforce our industrial foundation – they open doors to new economic opportunities and secure a brighter future for communities across the country. This is the kind of vision that propels our industry forward.”

About Stanley Black & Decker
Founded in 1843 and headquartered in the USA, Stanley Black & Decker (NYSE: SWK) is a worldwide leader in Tools and Outdoor, operating manufacturing facilities globally. The Company’s approximately 41,000 employees produce innovative end-user inspired power tools, hand tools, storage, digital jobsite solutions, outdoor and lifestyle products, and engineered fasteners to support the world’s builders, tradespeople and DIYers. The Company’s world class portfolio of trusted brands includes DEWALT®, CRAFTSMAN®, STANLEY®, BLACK+DECKER®, and Cub Cadet®. To learn more visit: www.stanleyblackanddecker.com or follow Stanley Black & Decker on Facebook, Instagram, LinkedIn and X.

Cautionary Note Regarding Forward-Looking Statements

Forward-looking statements, within the meaning of Section 27A of the Securities Act and Section 21E of the Securities Exchange Act of 1934, as amended, are made in this press release, including statements concerning Stanley Black & Decker’s investment, innovation and philanthropy initiatives and anticipated benefits from such initiatives. These forward-looking statements are sometimes identified from the use of forward-looking words such as “believe,” “should,” “could,” “potential,” “continue,” “expect,” “project,” “estimate,” “predict,” “anticipate,” “aim,” “intend,” “plan,” “forecast,” “target,” “is likely,” “will,” “can,” “may” or “would” or the negative of these terms or similar expressions elsewhere in this press release. All forward-looking statements are subject to a number of important factors, risks, uncertainties and assumptions that could cause actual results to differ materially from those described in any forward-looking statements. These factors and risks include, but are not limited to, Stanley Black & Decker’s ability to successfully implement its investment strategy, macroeconomic and geopolitical conditions and other financial, operational and legal risks and uncertainties detailed from time to time in the Company’s risk factors and cautionary statements contained in its filings with the Securities and Exchange Commission. These forward-looking statements represent the Company’s expectations as of the date of this press release. The Company disclaims, however, any intent or obligation to update these forward-looking statements.

SOURCE Stanley Black & Decker, Inc.

Source link

Octapharma To Build $1.5 Billion Critical Care Manufacturing Facility In South Carolina

Octapharma plans to invest $1.5 billion in its first U.S.-based manufacturing and production facility, creating approximately 1,500 full-time jobs in Rock Hill, South Carolina.

The 50-acre campus will be developed at Palmetto Research Park and is expected to become one of the largest private biomedical investments in South Carolina’s history.

The facility will produce plasma-derived therapies from Octapharma’s portfolio, establishing domestic manufacturing capabilities for medicines currently supported by the company’s international production network.

Octapharma also plans to manufacture bleeding management and trauma care products used for national security and emergency preparedness purposes.

The project is intended to reduce dependence on overseas pharmaceutical supply chains while bringing production closer to the plasma donated in the United States and the American patients who rely on the company’s treatments.

Octapharma selected Rock Hill following a planning and zoning process conducted with Rock Hill and York County officials and in coordination with local, state and federal leaders.

The company cited South Carolina’s advanced manufacturing infrastructure, logistics network, access to deep-water ports and growing biomedical workforce as factors supporting the location decision.

Octapharma expects demand for its existing therapies and future products to increase, requiring the company to expand its manufacturing capacity.

Construction and groundbreaking details will be announced at a later date.

Headquartered in Lachen, Switzerland, Octapharma develops and manufactures human protein therapies derived from human plasma and cell lines. The company has more than 11,000 employees and serves patients in 117 countries across immunotherapy, hematology and critical care.

Octapharma currently operates five European manufacturing facilities, seven research and development sites and more than 200 plasma donation centers across the United States and Europe.

KEY QUOTES:

“We expect significant future growth, driven by our existing life-saving therapies and a strong pipeline of new products. Our manufacturing capacity must evolve to support this ambition, and our U.S. manufacturing facility will be an important milestone. From a U.S. national security perspective, having the ability to produce and supply our therapies domestically is invaluable.”

Wolfgang Marguerre, CEO and Chairman of Octapharma

“We have built a significant presence in the U.S. over the last 20 years through our commercial capabilities, alongside our extensive network of plasma donation centers. As the demand in the U.S. for our portfolio of products continues to grow, the new U.S. manufacturing site will bring production of our FDA-approved therapies closer to both the plasma donated in the U.S. and to the patients who rely on them.”

Tobias Marguerre, Deputy Chairman of Octapharma

“Octapharma appreciates the good-faith work of every elected official and staff member in York County and Rock Hill who helped bring this to fruition. We also want to thank Governor McMaster and South Carolina’s federal and state delegation for their support in welcoming Octapharma to the Palmetto State.”

“South Carolina’s talented workforce, strong life sciences ecosystem and pro-business environment made it clear this was the right home for our first U.S. manufacturing facility.”

Flemming Nielsen, President of Octapharma USA

Thank you for visiting Pulse 2.0. We work hard every day to bring leaders and decision makers like you the latest intelligence on business, finance, capital markets, deal flow, law, tech, and AI. Click here to subscribe to the Pulse 2.0 Newsletter.

Source link

Octapharma To Build $1.5 Billion State-Of-The-Art Critical Care Manufacturing Facility In Rock Hill, SC

Octapharma, the largest privately owned and independent plasma fractionator in the world, has formally announced plans to establish its first-ever United States-based manufacturing and production site at the Palmetto Research Park in Rock Hill, South Carolina. The $1.5 billion project is expected to bring 1,500 full-time jobs to South Carolina, making it one of the largest private biomedical investments in the state’s history.

Once operations commence, the facility will produce critical, life-saving medicines from Octapharma’s portfolio of plasma-derived therapies, strengthening the domestic biomedical supply chain while complementing the company’s global manufacturing capabilities. The Rock Hill site will also produce bleeding management and trauma care products for national security and emergency preparedness needs. The announcement follows a thorough planning and zoning process coordinated with officials from Rock Hill and York County, alongside local, state, and federal leaders.

Rock Hill was selected for its proven infrastructure for advanced manufacturing, access to deep-water ports, and proximity to major logistics networks. South Carolina’s pipeline of biomedical and life sciences talent, supported by technical colleges and universities, is expected to provide the workforce needed to support the facility. Octapharma has built a significant US presence over the past 20 years through its commercial capabilities and extensive network of plasma donation centers, and the new site is intended to bring production of its FDA-approved therapies closer to both the plasma donated in the US and the patients who rely on them.

Octapharma is headquartered in Lachen, Switzerland, with more than 11,000 employees serving patients in 117 countries across Immunotherapy, Hematology, and Critical Care. The company operates 190 plasma donation centers across the United States and seven R&D sites and five manufacturing facilities in Europe. More details regarding a groundbreaking ceremony and construction timeline will be released at a later date.

KEY QUOTES:

“We expect significant future growth, driven by our existing life-saving therapies and a strong pipeline of new products. Our manufacturing capacity must evolve to support this ambition, and our US manufacturing facility will be an important milestone. From a US national security perspective, having the ability to produce and supply our therapies domestically is invaluable.”

Wolfgang Marguerre, CEO and Chairman, Octapharma

“We have built a significant presence in the US over the last 20 years through our commercial capabilities, alongside our extensive network of plasma donation centres. As the demand in the US for our portfolio of products continues to grow, the new US manufacturing site will bring production of our FDA-approved therapies closer to both the plasma donated in the US, and to the patients who rely on them.”

Tobias Marguerre, Deputy Chairman, Octapharma

“Octapharma appreciates the good-faith work of every elected official and staff member in York County and Rock Hill who helped bring this to fruition. South Carolina’s talented workforce, strong life sciences ecosystem, and pro-business environment made it clear this was the right home for our first US manufacturing facility.”

Flemming Nielsen, President, Octapharma USA

Thank you for visiting Pulse 2.0. We work hard every day to bring leaders and decision makers like you the latest intelligence on business, finance, capital markets, deal flow, law, tech, and AI. Click here to subscribe to the Pulse 2.0 Newsletter.

Source link

Apple commits more than $30 billion to US manufacturing

00:00 Speaker A

Last year, we made a $600 billion commitment to the US over four years, and now, as we said before, we plan to reinvest the tariff refunds we’ve received into the US.

00:09 Speaker A

We’re pleased with the progress we’ve already made advancing the American supply chain.

00:16 Speaker A

Earlier this month, Apple announced a new agreement with Broadcom to design and produce custom silicon components and cutting-edge wireless connectivity technologies.

00:27 Speaker A

The new multi-year agreement with Broadcom, which is part of Apple’s American manufacturing program, is expected to exceed $30 billion.

00:36 Speaker A

This marks our largest ever American manufacturing program commitment. It’s also an important step forward in our work to build an end-to-end silicon supply chain here in the US.

00:46 Speaker A

We’re excited for the upcoming opening of the Apple Advanced manufacturing Center in Houston.

00:52 Speaker A

The center is located in a facility where we currently assemble advanced AI servers.

00:59 Speaker A

Later this year, we’ll make Mac Mini there too.

01:03 Speaker A

The center will teach students, supplier employees, and business of all sizes the same innovative processes we use to make our products.

01:12 Speaker A

The goal is to empower American manufacturers to take their work to the next level and strengthen the entire advanced manufacturing ecosystem.

01:23 Speaker A

We have an exciting fall ahead and an incredible future beyond.

Source link

South Carolina Clears Final Approval for $1.5 Billion Plasma Manufacturing Campus

This content is the exclusive copyright of Construction Review Online (constructionreviewonline.com). Original URL: https://constructionreviewonline.com/octapharma-wins-final-approval-for-1-5-billion-plasma-manufacturing-campus-in-south-carolina/. © 2026 Group Africa. All rights reserved. Unauthorized reproduction, scraping or republication is strictly prohibited and constitutes wilful copyright infringement. If you are reading this on any site other than constructionreviewonline.com, the content has been stolen.

South Carolina officials have granted the final state and local approvals needed for a major pharmaceutical manufacturing investment in Rock Hill. Octapharma has secured final state and local approvals for a $1.5 billion plasma-derived therapies manufacturing campus in Rock Hill, South Carolina, paving the way for the company’s first U.S. plasma fractionation and manufacturing facility. The project will create more than 1,500 full-time jobs and add new U.S. manufacturing capacity for plasma-derived medicines when commercial operations begin in the mid-2030s.

The project was announced by Octapharma in partnership with the South Carolina Department of Commerce following final approvals from state and local authorities, including York County and the City of Rock Hill.

Octapharma will develop the campus at Palmetto Research Park in Rock Hill, York County. The development will include a plasma fractionation and manufacturing facility and an administrative headquarters for Octapharma Plasma, the company’s U.S. plasma donation subsidiary. With final approvals now secured, the company plans to announce a groundbreaking date and a detailed construction schedule at a later time.

Project Will Expand Domestic Plasma Manufacturing

Octapharma aims to strengthen the U.S. supply chain for plasma-derived therapies by locating large-scale manufacturing closer to its domestic plasma collection network and the patients who rely on these medicines. Company officials said the investment will also expand the nation’s capacity to manufacture plasma-derived therapies domestically, supporting long-term supply chain resilience and emergency preparedness. The company chose South Carolina for its proximity to Octapharma’s existing plasma donation network, well-developed transportation infrastructure and skilled biomedical workforce.

Plasma fractionation separates donated human plasma into therapeutic proteins that manufacturers use to produce medicines such as immunoglobulins, albumin and clotting factor therapies. Healthcare providers use these plasma-derived medicines to treat patients with immune deficiencies, bleeding disorders, neurological diseases and other serious medical conditions.

Support for the project

To support the project, South Carolina approved a $65 million Closing Fund grant to York County for site preparation, infrastructure improvements, construction-related work and road upgrades. The state’s Coordinating Council for Economic Development also approved Job Development Credits. Additional local incentive agreements, including any fee-in-lieu-of-tax arrangements or other tax abatements, have not yet been publicly disclosed.

“Our manufacturing capacity must evolve to support this ambition, and our U.S. manufacturing facility will be an important milestone,” Wolfgang Marguerre, chairman and CEO of Octapharma, said in a statement. “From a U.S. national security perspective, having the ability to produce and supply our therapies domestically is invaluable.”

South Carolina Gov. Henry McMaster said the investment reinforces the state’s position as a destination for advanced manufacturing and life sciences investment while creating new employment opportunities for South Carolina residents.

Growing Investment in U.S. Plasma Manufacturing

Pharmaceutical manufacturers continue to invest in U.S. production as they strengthen domestic supply chains for essential medicines. Companies including CSL Behring, Grifols and Takeda have expanded their U.S. plasma collection and manufacturing operations in recent years to meet growing global demand for plasma-derived therapies. The United States supplies most of the world’s source plasma because federal regulations allow compensated plasma donation, giving manufacturers access to a reliable donor base and making domestic production increasingly important to the global plasma industry.

Octapharma has not disclosed which specific plasma-derived products will initially be manufactured at the Rock Hill campus. Its existing portfolio includes immunoglobulins, albumin, clotting factor therapies and fibrin sealants. Before commercial production begins, the facility will be subject to applicable U.S. Food and Drug Administration inspections and biologics manufacturing approvals. The company has also not publicly detailed the phased construction and regulatory milestones behind its projected mid-2030s operational start.

Founded in 1983 and headquartered in Lachen, Switzerland, Octapharma develops plasma-derived and recombinant protein therapies and operates approximately 200 plasma donation centers across the United States through Octapharma Plasma. The Rock Hill campus will represent the company’s first plasma manufacturing operation in the U.S., marking a major expansion of its North American manufacturing footprint.

What’s Next

With approvals now secured, Octapharma can move forward with completing the property acquisition and preparing the site for construction. Additional project milestones, including groundbreaking and construction schedules, are expected to be announced as development progresses.

As pharmaceutical companies expand domestic manufacturing capacity for critical medicines, the Octapharma project joins other major U.S. life sciences investments aimed at strengthening healthcare supply chains. Another notable example is the $4.5B Eli Lilly medicine foundry in Indiana’s LEAP District, where Eli Lilly is developing a next-generation pharmaceutical manufacturing campus designed to accelerate medicine production through advanced manufacturing technologies. Together, the two projects highlight the broader trend of pharmaceutical companies investing billions of dollars in new U.S. manufacturing capacity to improve supply chain resilience and meet growing demand for advanced therapies.

Factsheet: Octapharma First U.S. Plasma Manufacturing Campus

• Developer: Octapharma AG
• Investment: $1.5 billion
• Location: Palmetto Research Park, Rock Hill, York County, South Carolina
• Facility Type: Plasma fractionation and manufacturing facility with an administrative headquarters
• Jobs Created: More than 1,500 full-time positions
• Construction Status: Final state and local approvals secured
• Groundbreaking: To be announced
• Projected Operations: Mid-2030s
• State Incentives: $65 million Closing Fund grant and Job Development Credits
• Primary Purpose: Expand U.S. manufacturing of plasma-derived therapies and strengthen domestic supply chain resilience
• Regulatory Status: Subject to applicable FDA inspections and biologics manufacturing approvals before commercial production
• Company Founded: 1983
• Headquarters: Lachen, Switzerland
• U.S. Plasma Collection Network: Approximately 200 plasma donation centers
• Significance: Octapharma’s first plasma fractionation and manufacturing facility in the United States.

Source: constructionreviewonline.com All rights reserved. Unauthorized reproduction prohibited.

Source link

Octapharma to build $1.5 billion state-of-the-art critical care manufacturing facility in Rock Hill, SC

New 50-acre campus will be one of the largest private biomedical investments in state’s history, bringing 1,500 jobs to South Carolina

Manufacturing facility will establish domestic production of Octapharma’s plasma-based therapies and products of national security concern, reducing dependency on overseas supply chains

PARAMUS, N.J., July 29, 2026 /PRNewswire/ — Octapharma, the largest privately owned and independent plasma fractionator in the world, has formally announced plans to establish its first-ever United States-based manufacturing and production site at the Palmetto Research Park in Rock Hill, South Carolina. The $1.5 billion project is expected to bring 1,500 full-time jobs to South Carolina, making this one of the largest private biomedical investments in the state’s history.  

Once operations commence, this facility will produce critical, life-saving medicines from Octapharma’s portfolio of plasma-derived therapies, strengthening the domestic biomedical supply chain while also complementing the company’s global manufacturing capabilities. Octapharma’s Rock Hill site will also produce bleeding management and trauma care products for national security and emergency preparedness needs.

Today’s announcement follows a thorough planning and zoning process coordinated with officials from Rock Hill and York County, and close partnership with local, state and federal leaders. 

“We expect significant future growth, driven by our existing life-saving therapies and a strong pipeline of new products,” said Wolfgang Marguerre, CEO and Chairman, Octapharma. “Our manufacturing capacity must evolve to support this ambition, and our US manufacturing facility will be an important milestone. From a US national security perspective, having the ability to produce and supply our therapies domestically is invaluable.”

“We have built a significant presence in the US over the last 20 years through our commercial capabilities, alongside our extensive network of plasma donation centres,” said Tobias Marguerre, Deputy Chairman, Octapharma. “As the demand in the US for our portfolio of products continues to grow, the new US manufacturing site will bring production of our FDA-approved therapies closer to both the plasma donated in the US, and to the patients who rely on them.”

Octapharma’s Commitment to Rock Hill
South Carolina’s leadership and Octapharma share a commitment to biomedical innovation, domestic supply chain resilience, and long-term economic investment in the surrounding community. 

With its proven infrastructure for advanced manufacturing, access to deep-water ports and proximity to major logistics networks, Rock Hill was selected as an ideal location for Octapharma’s first US facility. Additionally, South Carolina’s strong pipeline of biomedical and life sciences talent, supported by top-tier technical colleges and universities, will provide the workforce needed to support clean, efficient biopharmaceutical manufacturing at scale.

“Octapharma appreciates the good-faith work of every elected official and staff member in York County and Rock Hill who helped bring this to fruition,” said Flemming Nielsen, President, Octapharma USA. “We also want to thank Governor McMaster and South Carolina’s federal and state delegation for their support in welcoming Octapharma to the Palmetto State. South Carolina’s talented workforce, strong life sciences ecosystem, and pro-business environment made it clear this was the right home for our first US manufacturing facility.” 

More details regarding a groundbreaking ceremony and construction timeline will be released at a later date.  

To view the full release from the South Carolina Department of Commerce, please click here.  

About Octapharma
Octapharma is one of the world’s largest human protein manufacturers, developing and producing therapies from human plasma and human cell lines. Headquartered in Lachen, Switzerland, Octapharma has over 11,000 employees and serves patients in 117 countries across Immunotherapy, Hematology, and Critical Care. Octapharma has 190 plasma donation centers across the United States 

With seven R&D sites, five manufacturing facilities in Europe, and more than 200 plasma donation centers in the US and Europe, Octapharma has delivered trusted therapies for over 40 years. The company is committed to improving lives through innovation, quality, and a deep focus on patient care and clinical partnership. To learn more please visit www.octapharma.com. 

Media Contact:
Michael Steier
[email protected]
+1 (551) 410-7797

SOURCE Octapharma

Source link

Philip Morris Opens $1.2 Billion Manufacturing Campus In Colorado

Philip Morris International’s U.S. businesses have opened a new manufacturing campus in Aurora, Colorado, representing a planned investment of approximately $1.2 billion between 2024 and 2028.

The facility began commercial production in July 2026 and manufactures ZYN nicotine pouches. It joins PMI’s existing U.S. manufacturing operations in Owensboro, Kentucky, and Wilson, North Carolina.

Located on a 148-acre property, the approximately 780,000-square-foot campus is PMI’s first newly constructed manufacturing and production complex in the United States. The company said the project progressed from the start of construction to commercial shipments in approximately 19 months.

PMI initially announced the Aurora development as a $600 million project in 2024. The planned investment has since doubled as the company added production capacity, expanded the site and introduced additional infrastructure and manufacturing capabilities.

Approximately $1 billion of the planned $1.2 billion investment has already been incurred. The remaining capital is expected to support further development through 2028 as PMI responds to demand for ZYN in the United States and prepares the facility to serve international markets.

The campus integrates manufacturing, packaging, warehousing and distribution within one location. This structure is intended to improve operational efficiency and strengthen PMI’s supply chain by reducing reliance on any single production facility.

The Aurora operation is also being positioned as an export hub serving markets across Asia, Latin America and the Caribbean.

PMI expects the campus to directly employ approximately 500 people in production, engineering, quality control, technical and support roles.

Construction was projected to support nearly 5,000 jobs and generate close to $1 billion in economic activity. Once fully operational, the facility is expected to produce approximately $550 million in annual economic impact and support about 1,000 indirect jobs, according to an economic study cited by PMI.

The company has also contributed more than $1.5 million to Colorado organizations since 2024, including groups supporting veterans, utility assistance and workforce education.

The facility’s opening follows the U.S. Food and Drug Administration’s authorization of 20 ZYN products as modified-risk tobacco products in June 2026. The authorization allows PMI to communicate specified reduced-risk information relative to cigarettes under the conditions established by the agency.

KEY QUOTE:

“This facility expands our production capacity, strengthens our supply chain, and enhances our ability to serve growing demand in the United States and around the world.”

Stacey Kennedy, CEO of PMI U.S.

Thank you for visiting Pulse 2.0. We work hard every day to bring leaders and decision makers like you the latest intelligence on business, finance, capital markets, deal flow, law, tech, and AI. Click here to subscribe to the Pulse 2.0 Newsletter.

Source link

Micron’s $250 Billion Semiconductor Plant: Trump Highlights Historic Investment in U.S. Manufacturing – News and Statistics

Jul 11, 2026

Liz Claman delivered a live report from Clay, New York, where Micron is developing a memory chip fabrication facility with a price tag of $250 billion.

On Friday, President Donald Trump promoted Micron Technology‘s intention to allocate $250 billion toward U.S. semiconductor production, which the firm claims will become the biggest chip manufacturing site ever built in the country.

The enterprise headquartered in Boise, Idaho, revealed on Thursday that it is speeding up its domestic manufacturing and research expenditures, targeting 40% of its DRAM memory chip output to occur within the United States.

Trump posted on Truth Social that the move exemplifies what he called the Trump Effect, asserting that his administration is cutting regulations and reviving American industry after years of obstruction by prior Democratic leadership.

Micron anticipates spending over $250 billion by 2035, fueled by rising need for memory chips amid the artificial intelligence boom. The company noted that erecting the New York plant will demand thousands of skilled laborers, offering roles for union members, apprentices, graduates of local training initiatives, specialized contractors, and suppliers.

The project achieved its initial concrete placement at the Clay, New York, location on Thursday. Micron described it as the most substantial private investment in New York state history, projected to generate 50,000 jobs across the state, including 9,000 positions directly with Micron.

Micron further stated that its semiconductor operations in Idaho and Virginia, together with the New York endeavor, are anticipated to sustain an extra 90,000 jobs while bolstering U.S. economic and national security interests.

Trump also pointed to remarks from Micron President and CEO Sanjay Mehrotra, who indicated the company is raising its planned U.S. manufacturing and research outlay from $200 billion to $250 billion. Mehrotra explained that due to Trump’s leadership and policies, Micron is progressing ahead of schedule and expanding its investment, resulting in 100,000 American jobs. He characterized this as further proof of the Trump Effect driving unprecedented private-sector investment, domestic manufacturing, and employment growth.

Commerce Secretary Howard Lutnick applauded the announcement, stating that the Trump economic approach demonstrates there has never been a more favorable moment to invest in the United States. Kelly Loeffler, head of the U.S. Small Business Administration, remarked that the $250 billion commitment represents precisely the kind of daring, American-made pledge that President Trump’s strategy was intended to unleash.

Interactive table based on the Store Companies dataset for this report.

Sort: Rank
Sort: Company A-Z
Sort: Headquarters A-Z

#
Company
Headquarters
Focus
Scale
Note

1
Micron Technology
Boise, Idaho
DRAM, NAND Flash
Global leader
Major memory IC producer

2
Intel Corporation
Santa Clara, California
3D XPoint, Optane memory
Global giant
Developed advanced memory solutions

3
Western Digital
San Jose, California
NAND Flash, SSDs
Global leader
Flash memory via SanDisk

4
Seagate Technology
Fremont, California
Storage, HDD/SSD controllers
Global leader
Memory systems and controllers

5
Microchip Technology
Chandler, Arizona
Serial memory, EEPROM
Major supplier
Broad memory portfolio

6
SkyWater Technology
Bloomington, Minnesota
Foundry, memory IP
US-based foundry
Produces memory circuits

7
Rambus
San Jose, California
Memory interface IP, chips
IP and chip provider
High-speed memory interfaces

8
Lattice Semiconductor
Hillsboro, Oregon
FPGA, embedded memory
Mid-size
Devices include on-chip memory

9
Monolithic Power Systems (MPS)
San Jose, California
Power management, memory power
Major analog
ICs for memory modules

10
Marvell Technology
Santa Clara, California
Storage controllers, memory interconnect
Global fabless
SSD and memory controller chips

11
Analog Devices (ADI)
Wilmington, Massachusetts
Analog, memory interface ICs
Global giant
ICs for memory systems

12
Texas Instruments
Dallas, Texas
Embedded memory in MCUs/SoCs
Global giant
Memory integrated in devices

13
ON Semiconductor
Phoenix, Arizona
Power management for memory
Global supplier
Supporting memory ICs

14
MaxLinear
Carlsbad, California
RF, analog, memory interface
Fabless supplier
ICs for data storage

15
Integrated Silicon Solution Inc. (ISSI)
San Jose, California
SRAM, DRAM, Flash
Acquired by Chinese firm
US HQ, now subsidiary

16
Cypress Semiconductor (Infineon)
San Jose, California
SRAM, Flash, FRAM
Acquired
Was major US memory vendor

17
Macronix America
San Jose, California
NOR Flash memory
Subsidiary
US arm of Taiwan company

18
Integrated Device Technology (IDT)
San Jose, California
Memory interface, RISC-V
Acquired by Renesas
Was US-based

19
Silicon Motion Technology
San Jose, California
NAND flash controllers
Fabless, US HQ
Taiwanese-founded, US HQ

20
Netlist
Irvine, California
Hybrid memory modules, IP
Design and IP
Memory subsystem technology

21
Vishay Intertechnology
Malvern, Pennsylvania
Discrete, memory modules
Global manufacturer
Produces memory modules

22
SMART Modular Technologies
Newark, California
Memory modules, SSDs
Module manufacturer
Designs memory products

23
Adesto Technologies (Dialog)
Santa Clara, California
Low-power memory, CBRAM
Acquired
Was innovative memory vendor

24
Everspin Technologies
Chandler, Arizona
MRAM, persistent memory
Specialist
Leading MRAM producer

25
Aehr Test Systems
Fremont, California
Test systems for memory ICs
Equipment supplier
Critical for memory production

26
Rogue Valley Microdevices
Medford, Oregon
Foundry, memory prototyping
Small foundry
US-based memory IC maker

27
Nantero
Woburn, Massachusetts
NRAM, carbon nanotube memory
Startup
Developing novel memory ICs

28
Crossbar
Santa Clara, California
ReRAM, resistive RAM
Startup
Developing advanced memory ICs

29
Mythic
Austin, Texas
AI, analog in-memory compute
Startup
Memory-based AI chips

30
Weebit Nano
San Jose, California
ReRAM, embedded memory
Startup
US HQ for Israel-based tech

This report provides a comprehensive view of the memories industry in the United States, tracking demand, supply, and trade flows across the national value chain. It explains how demand across key channels and end-use segments shapes consumption patterns, while also mapping the role of input availability, production efficiency, and regulatory standards on supply.

Beyond headline metrics, the study benchmarks prices, margins, and trade routes so you can see where value is created and how it moves between domestic suppliers and international partners. The analysis is designed to support strategic planning, market entry, portfolio prioritization, and risk management in the memories landscape in the United States.

Quick navigation

Key findings

• Domestic demand is shaped by both household and industrial usage, with trade flows linking local supply to imports and exports.
• Pricing dynamics reflect unit values, freight costs, exchange rates, and regulatory shifts that affect sourcing decisions.
• Supply depends on input availability and production efficiency, creating a distinct national cost curve.
• Market concentration varies by segment, creating different competitive landscapes and entry barriers.
• The 2035 outlook highlights where capacity investment and demand growth are most aligned within the country.

Report scope

The report combines market sizing with trade intelligence and price analytics for the United States. It covers both historical performance and the forward outlook to 2035, allowing you to compare cycles, structural shifts, and policy impacts.

• Market size and growth in value and volume terms
• Consumption structure by end-use segments
• Production capacity, output, and cost dynamics
• Trade flows, exporters, importers, and balances
• Price benchmarks, unit values, and margin signals
• Competitive context and market entry conditions

Product coverage

• Prodcom 26113023 – Multichip integrated circuits: memories
• Prodcom 26113027 – Electronic integrated circuits (excluding multichip circuits): dynamic random-access memories (D-RAMs)
• Prodcom 26113034 – Electronic integrated circuits (excluding multichip circuits): static random-access memories (S-RAMs), including cache random-access memories (cache-RAMs)
• Prodcom 26113054 – Electronic integrated circuits (excluding multichip circuits): UV erasable, programmable, read only memories (EPROMs)
• Prodcom 26113065 – Electronic integrated circuits (excluding multichip circuits): electrically erasable, programmable, read only memories (E.PROMs), including flash E.PROMs
• Prodcom 26113067 – Electronic integrated circuits (excluding multichip circuits): other memories

Country coverage

Country profile and benchmarks

This report provides a consistent view of market size, trade balance, prices, and per-capita indicators for the United States. The profile highlights demand structure and trade position, enabling benchmarking against regional and global peers.

Methodology

The analysis is built on a multi-source framework that combines official statistics, trade records, company disclosures, and expert validation. Data are standardized, reconciled, and cross-checked to ensure consistency across time series.

• International trade data (exports, imports, and mirror statistics)
• National production and consumption statistics
• Company-level information from financial filings and public releases
• Price series and unit value benchmarks
• Analyst review, outlier checks, and time-series validation

All data are normalized to a common product definition and mapped to a consistent set of codes. This ensures that comparisons across time are aligned and actionable.

Forecasts to 2035

The forecast horizon extends to 2035 and is based on a structured model that links memories demand and supply to macroeconomic indicators, trade patterns, and sector-specific drivers. The model captures both cyclical and structural factors and reflects known policy and technology shifts in the United States.

• Historical baseline: 2012-2025
• Forecast horizon: 2026-2035
• Scenario-based sensitivity to income growth, substitution, and regulation
• Capacity and investment outlook for major producing companies

Each projection is built from national historical patterns and the broader regional context, allowing the report to show where growth is concentrated and where risks are elevated.

Price analysis and trade dynamics

Prices are analyzed in detail, including export and import unit values, regional spreads, and changes in trade costs. The report highlights how seasonality, freight rates, exchange rates, and supply disruptions influence pricing and margins.

• Price benchmarks by country and sub-region
• Export and import unit value trends
• Seasonality and calendar effects in trade flows
• Price outlook to 2035 under baseline assumptions

Profiles of market participants

Key producers, exporters, and distributors are profiled with a focus on their operational scale, geographic footprint, product mix, and market positioning. This helps identify competitive pressure points, partnership opportunities, and routes to differentiation.

• Business focus and production capabilities
• Geographic reach and distribution networks
• Cost structure and pricing strategy indicators
• Compliance, certification, and sustainability context

How to use this report

• Quantify domestic demand and identify the most attractive segments
• Evaluate export opportunities and prioritize target destinations
• Track price dynamics and protect margins
• Benchmark performance against leading competitors
• Build evidence-based forecasts for investment decisions

This report is designed for manufacturers, distributors, importers, wholesalers, investors, and advisors who need a clear, data-driven picture of memories dynamics in the United States.

FAQ

What is included in the memories market in the United States?

The market size aggregates consumption and trade data, presented in both value and volume terms.

How are the forecasts to 2035 built?

The projections combine historical trends with macroeconomic indicators, trade dynamics, and sector-specific drivers.

Does the report cover prices and margins?

Yes, it includes export and import unit values, regional spreads, and a pricing outlook to 2035.

Which benchmarks are included?

The report benchmarks market size, trade balance, prices, and per-capita indicators for the United States.

Can this report support market entry decisions?

Yes, it highlights demand hotspots, trade routes, pricing trends, and competitive context.

1. 1. INTRODUCTION

   Report Scope and Analytical Framing

   1. Report Description
   2. Research Methodology and the Analytical Framework
   3. Data-Driven Decisions for Your Business
   4. Glossary and Product-Specific Terms

2. 2. EXECUTIVE SUMMARY

   Concise View of Market Direction

   1. Key Findings
   2. Market Trends
   3. Strategic Implications
   4. Key Risks and Watchpoints

3. 3. DOMESTIC MARKET SIZE AND DEVELOPMENT PATH

   Market Size, Growth and Scenario Framing

   1. Market Size: Historical Data (2012-2025) and Forecast (2026-2035)
   2. Growth Outlook and Market Development Path to 2035
   3. Growth Driver Decomposition
   4. Scenario Framework and Sensitivities

4. 4. CATEGORY SCOPE, DEFINITIONS AND BOUNDARIES

   Commercial and Technical Scope

   1. What Is Included and How the Market Is Defined
   2. Market Inclusion Criteria
   3. Product / Category Definition
   4. Exclusions and Boundaries
   5. Distinction From Adjacent Products and Substitute Categories

5. 5. CATEGORY STRUCTURE, SEGMENTATION AND PRODUCT MATRIX

   How the Market Splits Into Decision-Relevant Buckets

   1. By Product Type / Configuration
   2. By Application / End Use
   3. By Customer / Buyer Type
   4. By Channel / Business Model / Technology Platform
   5. Segment Attractiveness Matrix
   6. Product Matrix and Segment Growth Logic

6. 6. DOMESTIC DEMAND, CUSTOMER AND BUYER ARCHITECTURE

   Where Demand Comes From and How It Behaves

   1. Consumption / Demand: Historical Data (2012-2025) and Forecast (2026-2035)
   2. Demand by End-Use and Buyer Group
   3. Demand by Customer / Consumer Segment
   4. Purchase Criteria, Switching Logic and Adoption Barriers
   5. Replacement, Replenishment and Installed-Base Dynamics
   6. Future Demand Outlook

7. 7. DOMESTIC PRODUCTION, SUPPLY AND VALUE CHAIN

   Supply Footprint and Value Capture

   1. Production in the Country
   2. Domestic Manufacturing Footprint
   3. Capacity, Bottlenecks and Supply Risks
   4. Value Chain Logic and Margin Pools
   5. Distribution and Route-to-Market Structure

8. 8. IMPORTS, EXPORTS AND SOURCING STRUCTURE

   Trade Flows and External Dependence

   1. Exports
   2. Imports
   3. Trade Balance
   4. Import Dependence
   5. Sourcing Risks and Resilience

9. 9. PRICING, PROMOTION AND COMMERCIAL MODEL

   Price Formation and Revenue Logic

   1. Domestic Price Levels and Corridors
   2. Pricing by Segment / Specification / Channel
   3. Cost Drivers and Margin Logic
   4. Promotion, Discounting and Procurement Patterns
   5. Revenue Quality and Commercial Levers

10. 10. COMPETITIVE LANDSCAPE AND PORTFOLIO POWER

    Who Wins and Why

    1. Market Structure and Concentration
    2. Competitive Archetypes
    3. Segment-by-Segment Competitive Intensity
    4. Portfolio Breadth and Product Positioning
    5. Capability Matrix
    6. Strategic Moves, Partnerships and Expansion Signals

11. 11. DOMESTIC MARKET STRUCTURE AND CHANNEL LOGIC

    How the Domestic Market Works

    1. Core Demand Centers
    2. Local Production and Distribution Roles
    3. Channel Structure
    4. Buyer and Procurement Architecture
    5. Regional Imbalances Within the Country

12. 12. GROWTH PLAYBOOK AND MARKET ENTRY

    Commercial Entry and Scaling Priorities

    1. Where to Play
    2. How to Win
    3. Distributor / Partner / Direct Entry Options
    4. Capability Thresholds
    5. Entry Risks and Mitigation

13. 13. WHERE TO PLAY NEXT: MOST ATTRACTIVE GROWTH OPPORTUNITIES

    Where the Best Expansion Logic Sits

    1. Most Attractive Product Niches
    2. Most Attractive Customer Segments
    3. White Spaces and Unsaturated Opportunities
    4. High-Margin and Underpenetrated Pockets
    5. Most Promising Product Adjacencies

14. 14. PROFILES OF MAJOR COMPANIES

    Leading Players and Strategic Archetypes

    1. Leading Manufacturers and Suppliers
    2. Production Footprint and Capacities
    3. Product Portfolio and Segment Focus
    4. Pricing Positioning and Indicative Price Logic
    5. Channel / Distribution Strength
    6. Strategic Archetypes

15. 15. METHODOLOGY, SOURCES AND DISCLAIMER

    How the Report Was Built

    1. Modeling Logic
    2. Source Register
    3. Publications, Regulatory and Industry References
    4. Analytical Notes
    5. Disclaimer

Loading News content from Store report…

Micron Technology

Major memory IC producer

Intel Corporation

Developed advanced memory solutions

Western Digital

Flash memory via SanDisk

Seagate Technology

Memory systems and controllers

Microchip Technology

Broad memory portfolio

SkyWater Technology

Produces memory circuits

Rambus

High-speed memory interfaces

Lattice Semiconductor

Devices include on-chip memory

Monolithic Power Systems (MPS)

ICs for memory modules

Marvell Technology

SSD and memory controller chips

Analog Devices (ADI)

ICs for memory systems

Texas Instruments

Memory integrated in devices

ON Semiconductor

Supporting memory ICs

MaxLinear

ICs for data storage

Integrated Silicon Solution Inc. (ISSI)

US HQ, now subsidiary

Cypress Semiconductor (Infineon)

Was major US memory vendor

Macronix America

US arm of Taiwan company

Integrated Device Technology (IDT)

Was US-based

Silicon Motion Technology

Taiwanese-founded, US HQ

Netlist

Memory subsystem technology

Vishay Intertechnology

Produces memory modules

SMART Modular Technologies

Designs memory products

Adesto Technologies (Dialog)

Was innovative memory vendor

Everspin Technologies

Leading MRAM producer

Aehr Test Systems

Critical for memory production

Rogue Valley Microdevices

US-based memory IC maker

Nantero

Developing novel memory ICs

Crossbar

Developing advanced memory ICs

Mythic

Memory-based AI chips

Weebit Nano

US HQ for Israel-based tech

Loading Reviews content from Store report…

Loading Dashboard content from Store report…

Loading Macro Indicators content from Store report…

Source link

Micron to Pour $250 Billion in Manufacturing on US Soil As It Starts Construction of New York’s DRAM Megafab

Micron has announced that it will invest $250 billion in America as it lays down the first concrete for the New York DRAM Megafab.

Micron Aims To Make 40% of Its Total DRAM In America While Creating Over 90,000 Jobs Through A $250B Commitment

DRAM demand surge has boosted revenues of all major manufacturers, including Micron, as such, the company has laid down a $250 billion commitment through 2035, which will accelerate the AI segment fruther.

Today is a proud day for Micron and American manufacturing. 🇺🇸

We’re increasing our planned U.S. manufacturing and R&D investment commitment to more than $250B, supporting our goal of producing 40% of our DRAM in America and creating 90,000+ jobs.

We also poured the first… pic.twitter.com/5pFxRl1AtW

— Sanjay Mehrotra (@MicronCEO) July 9, 2026

The initiative is simple: $250 billion of investments through 2035 towards major manufacturing and R&D centers across America. This long-term goal will achieve 40% of Micron’s global DRAM production on US soil, while creating nearly 100,000 jobs in the country.

As part of this commitment, Micron celebrated the announcement with the first concrete pour milestone at its New York DRAM Megafab, which is located in Clay. The milestone is said to be achieved one quarter ahead of the original plan, and the construction will now go vertical. The company is also investing up to $3 billion in the development of a domestic semiconductor supply chain ecosystem.

Today, Micron Chairman, President and CEO Sanjay Mehrotra will host the concrete pour, joined by supplier partners and federal, state and local leaders, including U.S. Secretary of Commerce Howard Lutnick, New York Governor Kathy Hochul, Small Business Administration Administrator Kelly Loeffler, U.S. Chief Technology Officer Dr. Ethan Klein, Onondaga County Executive Ryan McMahon, U.S. Congressman John Mannion, U.S. Congresswoman Claudia Tenney, and Town of Clay Deputy Supervisor Joe Bick.

This commitment goes in line with US President Donald J Trump’s “Made in the USA” policy, with major firms such as Intel, NVIDIA, and AMD all focusing on producing their chips domestically. TSMC has already laid out plans to build major fabs throughout the US in a bid to bring advanced manufacturing capabilities to the US.

“President Trump has made it clear that America is where you should build your business and the world is responding rapidly. Today, Micron pours the foundation on its massive semiconductor campus in upstate New York and increases its American investment commitment to $250 billion, creating nearly 100,000 jobs and providing leading-edge memory supply here in the United States,” said Commerce Secretary Howard Lutnick. “The Trump economic model clearly shows there has never been a better time to invest in the United States.”

Talking a bit about its major fabs, the ones in Idaho are said to be making rapid progress and are expected to have first wafer output by mid 2027 for the first fab and late 2028 for the second fab.

Micron is definitely going big with its manufacturing capabilities, which was a given considering just how massive the demand for DRAM and NAND is right now. The company is already engaged with several customers in what it refers to as “Strategic Customer Agreements,” which are hard-locked deals to ensure that the committed memory supply is delivered to these high-level parties at a finalized rate within a 3-5 year timeframe.

Today’s milestone, pouring the first concrete at its New York DRAM Megafab ahead of schedule, symbolizes a new era of advanced manufacturing “Made in the USA.” With strong government support and surging demand, Micron’s ambitious expansion positions the United States at the forefront of next-generation memory technology.

About the author: A Software Engineer by training and a PC enthusiast by passion, Hassan Mujtaba serves as Wccftech’s Senior Editor for hardware section. With years of experience in the industry, he specializes in deep-dive technical analysis of next-generation CPU and GPU architectures, motherboards, and cooling solutions. His work involves not only breaking news on upcoming technologies but also extensive hands-on reviews and benchmarking.

Follow Wccftech on Google to get more of our news coverage in your feeds.

Source link

Pirelli Plans Up to $1.2 Billion U.S. Investment, Expanding Focus on Rome Plant

Tire manufacturer Pirelli is planning to invest between $1 billion and $1.2 billion in its U.S. operations over the coming years, a move expected to further strengthen production at its Rome manufacturing facility.

The Italian company announced that its newly appointed board of directors had been informed of the multi-year investment plan, which will be presented for formal approval at an upcoming board meeting.

The investment is aimed at increasing Pirelli’s manufacturing capacity in the United States, including expanding production of its innovative Cyber Tyres.

In May, Pirelli announced that Cyber Tyres would be produced at its Rome, Georgia, plant, positioning the northwest Georgia facility at the forefront of the company’s next generation of tire technology.

Cyber Tyre technology integrates sensors embedded inside the tire with software capable of transmitting real-time data to vehicles. The system can monitor information such as tire pressure, temperature and road conditions, providing drivers and vehicle systems with enhanced safety and performance data.

The planned investment underscores the strategic importance of Pirelli’s U.S. manufacturing operations as demand grows for advanced tire technologies.

The announcement also comes amid significant changes to the company’s corporate governance.

Earlier this year, the Italian government stepped in to limit the influence of Pirelli’s largest shareholder, Chinese state-owned chemical company Sinochem, citing concerns that its ownership structure could affect the tire maker’s business opportunities in the United States.

Following those restrictions, shareholders approved a new board of directors last week that is controlled by Italian investor Camfin, the investment company led by longtime Pirelli executive Marco Tronchetti Provera.

Camfin owns a 26.2% stake in Pirelli, while Sinochem remains the company’s largest shareholder with a 34.1% stake. However, under the new board structure, Sinochem secured just three seats on the 15-member board.

On Tuesday, the board confirmed Andrea Casaluci as Pirelli’s chief executive officer and appointed Tronchetti Provera as executive chairman after he previously served as executive vice chairman.

For Rome, where Pirelli has operated one of its largest North American manufacturing facilities for decades, the investment signals continued confidence in the plant’s future. The company’s decision earlier this year to manufacture Cyber Tyres in Rome places the local facility at the center of Pirelli’s U.S. growth strategy and positions it to play a key role as the automotive industry increasingly adopts connected vehicle technologies.

Source link